GlassScriptPhysician profile
Tedi Begaj
NPI 1003348905
$7,751.41
in general payments reported to CMS, 2019-2025
13 companies · $516 in 2025
The $516 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $190 · 2022: $1,696 · 2023: $938 · 2024: $4,412 · 2025: $516.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,516 · Honoraria: $350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,515.74 |
| Honoraria | $350.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alimera Sciences, INC. | $3,937.00 | 2023-2024 | Iluvien, Yutiq |
| Eyepoint US, INC. | $1,300.97 | 2021-2023 | |
| Bausch & Lomb Americas INC. | $776.58 | 2022-2025 | Xipere, Visudyne, Stellaris |
| Regeneron Healthcare Solutions, INC. | $420.93 | 2021-2025 | Eylea Hd, Eylea |
| Astellas Pharma US INC | $295.48 | 2024-2025 | Izervay |
| Abbvie INC. | $251.05 | 2022-2025 | |
| Genentech USA, INC. | $248.00 | 2022 | |
| Coherus Oncology, INC. | $135.00 | 2023 | |
| Oculus Surgical INC. | $124.15 | 2024 | |
| Apellis Pharmaceuticals, INC. | $124.00 | 2022 | |
| Ani Pharmaceuticals, INC. | $77.26 | 2024-2025 | Yutiq, Purified Cortrophin Gel |
| Alcon Vision LLC | $44.80 | 2021 | |
| Dutch Ophthalmic, USA | $16.19 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tedi Begaj listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.